Illumina CTO, CMO depart
Plus: Auron hires Guiffre and updates from Karius and Foresite
Illumina Inc. (NASDAQ:ILMN) announced the departures of CMO Phil Febbo and CTO Alex Aravanis, changes to the C-suite that come weeks after the resignation of CEO Francis deSouza in June and the failure of Chairman John Thompson to win re-election in May. Aravanis is succeeded by VP and Head of Global Advanced Science Steven Barnard; a successor to Febbo has yet to be announced. Illumina also reported its 2Q23 earnings — the company recorded revenue of $1.2 billion, an increase of 1% compared with 2Q22, but cut its non-GAAP diluted EPS guidance to $0.75-$0.90 for fiscal 2023 from $1.25-$1.50.
Auron Therapeutics Inc. hired Chris Guiffre as president and COO and appointed Victoria Richon to its board. Guiffre was CFO and COO at Pear Therapeutics Inc. (NASDAQ:PEAR). Richon is CEO of Entact Bio Inc., which she helped launch in December. Auron is developing cancer therapies targeting cellular differentiation pathways discovered via machine learning analyses of multi-omics datasets...